A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
Status:
Not yet recruiting
Trial end date:
2025-06-07
Target enrollment:
Participant gender:
Summary
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy
of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with
Relapsed/Refractory DLBCL and iNHL Who are Ineligible for High-dose Chemotherapy (HDC) or
Autologous Stem Cell Transplant (A SCT).